SCHEMBL25869491

SCHEMBL25869491

CCCCCCCCCCCCOCC(O)CNCCN1CCCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 2/20 0.48
HTT P42858 1/20 0.47
LMNA P02545 1/20 0.44
LTA4H P09960 1/20 0.42
LPAR5 Q9H1C0 1/20 0.42
KDM4E B2RXH2 3/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
CASR P41180 1/20 0.39
ALDH1A1 P00352 2/20 0.38
ALOX15 P16050 1/20 0.38
THRA P10827 2/20 0.38
THRB P10828 2/20 0.38
GNAI3 P08754 2/20 0.38
GNAO1 P09471 2/20 0.38
GNAI1 P63096 2/20 0.38
SPHK1 Q9NYA1 1/20 0.38
ADRB3 P13945 1/20 0.37
PLA2G2C Q5R387 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25869487 0.99 USP2 (0.47) USP2HTTLMNALTA4HLPAR5
SCHEMBL10969687 0.83 USP2 (0.56) USP2HTTLTA4HLPAR5KDM4E
SCHEMBL10969690 0.83 USP2 (0.56) USP2HTTLTA4HLPAR5KDM4E
SCHEMBL21019381 0.81 USP2 (0.61) USP2HTTLPAR5KDM4ECYP1A2
SCHEMBL15393759 0.81 USP2 (0.61) USP2HTTLPAR5KDM4ECYP1A2
SCHEMBL1244447 0.79 LMNA (0.40) LMNAKDM4EALDH1A1
SCHEMBL17416191 0.79 LMNA (0.36) LMNAKDM4EADRB3
SCHEMBL17416211 0.79 LMNA (0.36) LMNAKDM4EADRB3
SCHEMBL25121001 0.79 LMNA (0.50) LMNAKDM4EALDH1A1
SCHEMBL314577 0.79 USP2 (0.62) USP2HTTLPAR5KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233468-A1 LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS Suzhou Abogen Biosciences Co., Ltd. (CN) 2023-07-27 US disclosed
US-20230233468-A1 LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS Suzhou Abogen Biosciences Co., Ltd. (CN) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233468-A1 LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS CETP, NPC1, LCAT USP2 2151/4885HTT 959/4885LMNA 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.